This is the first quarter Scholar Rock has ever booked product revenue, from initial ISEMBYLD stocking shipments after the September 11 FDA approval in SMA. More than a third of the top 140 U.S. treatment centers have already enrolled patients, though a drug-specific J-code does not arrive until April 2027.
Latest Activity
SRRK Coverage
Three Biotechs That Are Top Takeover Targets
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…
Insiders Bet Big on These 3 Fintech and Biotech Stocks
In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were not the only notable insider purchases recently.
Wall Street Insiders Are Loading Up on These 3 Stocks
People don’t like to throw money into a sinking ship, and by that logic, insider buys in Wall Street can be an easy way to gauge how well a company might do…